Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience

INTRODUCTION: There are three combination immune checkpoint inhibitor (ICI)–based regimens in the first-line setting for metastatic renal cell carcinoma (mRCC). Currently, there is limited real-world data for clinical outcomes and toxicity in mRCC patients treated with first-line ICI-based regimens....

Descripción completa

Detalles Bibliográficos
Autores principales: Martini, Dylan J., Olsen, T. Anders, Goyal, Subir, Liu, Yuan, Evans, Sean T., Hitron, Emilie Elise, Russler, Greta Anne, Yantorni, Lauren, Caulfield, Sarah, Brown, Jacqueline T., Goldman, Jamie M., Nazha, Bassel, Carthon, Bradley C., Harris, Wayne B., Kucuk, Omer, Master, Viraj A, Bilen, Mehmet Asim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Innovative Healthcare Institute 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390705/
https://www.ncbi.nlm.nih.gov/pubmed/36034580
http://dx.doi.org/10.36401/JIPO-22-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390705/
https://www.ncbi.nlm.nih.gov/pubmed/36034580
http://dx.doi.org/10.36401/JIPO-22-2

Ejemplares similares